Search results for "Bimatoprost"

showing 2 items of 2 documents

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Uso della monoterapia con Bimatoprost nella clinica quotidiana

2011

Gli Autori riportano i risultati di uno studio multicentrico,prospettico, osservazionale condotto nel 2010 sull'uso nella pratica clinica della monoterapia con l'analogo prostanidico ,Bimatoprost 0.3 mg/ml, in pazienti con glaucoma cronico ad angolo aperto mai trattati in precedenza se non con farmaci betabloccanti.

Tonometria .BimatoprostGlaucoma cronicoSettore MED/30 - Malattie Apparato VisivoCompliance
researchProduct